GCTK Glucotrack, Inc.

Nasdaq Surgical & Medical Instruments & Apparatus DE CIK: 0001506983
AI RATING
STRONG_SELL
97% Confidence

Investment Thesis

Glucotrack exhibits critical financial distress with negative stockholders' equity of -$851K, virtually no revenue ($2.3K), and operating losses of -$4.2M. The company is burning approximately $4M annually with only ~$3.9M in cash reserves, indicating minimal runway before potential insolvency.

Strengths

  • + Maintains $3.9M in cash reserves providing short-term liquidity buffer
  • + Capital expenditures are minimal at $96K, limiting further cash drain from investments
  • + Company maintains SEC compliance and reporting obligations

Risks

  • ! Negative stockholders' equity (-$851K) and liabilities exceeding assets indicate technical insolvency
  • ! Operating cash burn of -$4.0M annually against minimal revenue creates less than 1-year cash runway
  • ! Massive operating losses (-$4.2M) on revenue base of only $2.3K indicates no viable business model

Key Metrics to Watch

Financial Metrics

Revenue
2.3K
Net Income
-4.3M
EPS (Diluted)
$2.65
Free Cash Flow
-4.1M
Total Assets
4.4M
Cash
3.9M

Profitability Ratios

Gross Margin N/A
Operating Margin -185,072.7%
Net Margin -190,841.0%
ROE N/A
ROA -99.5%
FCF Margin -182,474.7%

Balance Sheet & Liquidity

Current Ratio
0.85x
Quick Ratio
0.84x
Debt/Equity
N/A
Debt/Assets
119.5%
Interest Coverage
-95.52x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: 2026-05-15T09:25:12.799717 | Data as of: 2026-03-31 | Powered by Claude AI